Compare Global X Defense Tech ETF (SHLD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Sanofi SA — how do they compare? Global X Defense Tech ETF trades at $61.96, while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA pays a 5.61% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals.
| SHLD | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $52.34 |
52-Week Low | $58.20 | $41.33 |
Market Cap | — | $104.06B |
Enterprise Value | — | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $62.72, down 0.41% on the day, with a bearish technical signal overall despite oversold RSI readings. The ETF offers diversified exposure to global defense technology firms, with institutional buying interest noted in recent filings. Key support sits at $62, while resistance is at $63-$64.
Outlook is supported by rising global defense spending and geopolitical shifts, but risks include high launch costs for space-related holdings and ETF expense comparisons. The technical setup suggests potential for a near-term rebound from oversold levels, though moving averages remain bearish.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
